COYA 302, Coya Therapeutics’ experimental immune-modulating combination therapy, safely slows disease progression and reduces levels of disease biomarkers in…
Articles by Steve Bryson, PhD
People with amyotrophic lateral sclerosis (ALS) who are treated by a neurologist are more likely to receive evidence-based care…
A new amyotrophic lateral sclerosis (ALS) assessment called delta-FS — defined as the rate of decline over time in…
Target ALS has reached its capital campaign goal of $250 million to accelerate research and fuel scientific breakthroughs in…
Epigenetic changes — chemical modifications in DNA that alter gene activity — in nerve cells from people with amyotrophic…
Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS)…
The developer of the add-on treatment masitinib for amyotrophic lateral sclerosis (ALS) has been given the go-ahead to…
Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for amyotrophic lateral sclerosis (ALS), was voluntarily removed from the…
More than a third of people diagnosed with amyotrophic lateral sclerosis (ALS) also showed signs of…
AcuraStem has secured nearly $7 million in grant funding from the National Institutes of Health (NIH)…